# Frontline Risk-Adapted Optimization of Novel Targeted Immunotherapy Evaluation in High-Risk MCL

> **NCT07569965** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Miltenyi Biomedicine GmbH** · enrollment: 52 (estimated)

## Conditions studied

- Mantle Cell Lymphoma (MCL)

## Interventions

- **BIOLOGICAL:** zamtocabtagene autoleucel (MB-CART2019.1)
- **DRUG:** Cyclophosphamide
- **DRUG:** Fludarabine

## Key facts

- **NCT ID:** NCT07569965
- **Lead sponsor:** Miltenyi Biomedicine GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-09
- **Primary completion:** 2029-09
- **Final completion:** 2030-03
- **Target enrollment:** 52 (ESTIMATED)
- **Last updated:** 2026-05-06

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07569965

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07569965, "Frontline Risk-Adapted Optimization of Novel Targeted Immunotherapy Evaluation in High-Risk MCL". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT07569965. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*